Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

NCT05315700 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: ORIC-114
DRUG: Chemotherapy drug

Sponsor

ORIC Pharmaceuticals